| Trial | control | p<0.05 | harm | NS |
|---|
| EORTC18871/DKG 80-1 (Kleeberg), 2004 | rIFN alpha-2b vs observation | | | OS 0.96 [0.76; 1.21] PFS 1.04 [0.84; 1.29] |
| EORTC18952 (Eggermont), 2005 | ID IFN alpha-2b (I M) vs observation | | | OS 0.84 [0.66; 1.07] PFS 0.84 [0.67; 1.06] DMFS 0.84 [0.66; 1.07] |
| EORTC18991 (Eggermont), 2008 | PEG IFN alpha-2b (I M) vs observation | PFS 0.87 [0.76; 1.00] | | OS 0.96 [0.83; 1.12] DMFS 0.93 [0.81; 1.07] |
| Nordic IFN Trial, 2011 | ID IFN alpha-2b (I M) vs observation | PFS 0.77 [0.62; 0.95] | | OS 0.91 [0.72; 1.15] |
| Trial | Treatments | Patients | Method |
|---|
| EORTC18871/DKG 80-1 (Kleeberg), 2004 | rIFN-alpha2b (n=-9) vs. observation (n=-9) 4 arms: IFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation | High-risk stage II patients (thickness >3 mm) and stage III patients (positivelymph nodes) without distant metastasis | Sample size: -9/-9 Primary endpoint: FU duration: 8.2 years (median) |
| EORTC18952 (Eggermont), 2005 | (n=-9) vs. (n=-9) | patients who had had a thick primary tumour (thickness4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) | Sample size: -9/-9 Primary endpoint: FU duration: 4.65 years |
| EORTC18991 (Eggermont), 2008 | pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years (n=627) vs. (n=629) | patients with resected stage III melanoma | Sample size: 627/629 Primary endpoint: recurrence-free survival FU duration: 3.8 years |
| Nordic IFN Trial, 2011 | intermediate-dose interferon alfa-2b duration 1 (n=-9) vs. duration 2 (n=-9) | patients with stage IIB-IIC or III resected cutaneous melanoma. | Sample size: -9/-9 Primary endpoint: FU duration: 72·4 months |
